A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

Brief description of study

Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24.

Description of the:

  • Change in disease activity after 16 and 24 weeks
  • Change in subject and family quality of life after 16 and 24 weeks
  • Change in sleep quality after 16 and 24 weeks
  • Change in anxiety after 16 and 24 weeks
  • Change in depression after 16 and 24 weeks
  • Safety and tolerability

Detailed description of study

28 weeks

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atopic Dermatitis
  • Age: 18 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patient eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL
  • Signed informed consent
  • 18 years and older (study questionnaires are validated for this age group). Patient is able to follow the prescribed regimen, routine follow-up visits and to fill the questionnaires

Exclusion Criteria:

  • Patient not eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL.
        The above information is not intended to contain all considerations relevant to a potential
        participation in a clinical trial.

Updated on 07 Mar 2023 . Study ID: NCT05527964

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site